Non Infective Diarrhea — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for non infective diarrhea. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
2
Active US patents
68/100
Avg vulnerability
—
Annual revenue covered

Originators in Non Infective Diarrhea

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Napo Pharms Inc 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating non infective diarrhea. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Mytesi
CROFELEMER
 Napo Pharms Inc 2 68 — 2031-10-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8962680 Mytesi method of use 68 2031-10-31
9585868 Mytesi method of use 68 2031-10-31

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8962680 Mytesi method of use 68 2031-10-31
9585868 Mytesi method of use 68 2031-10-31

Related